Essential Planning LLC. Takes Position in COMPASS Pathways plc (NASDAQ:CMPS)

Essential Planning LLC. bought a new stake in COMPASS Pathways plc (NASDAQ:CMPS) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 18,395 shares of the company’s stock, valued at approximately $70,000.

Several other institutional investors and hedge funds have also made changes to their positions in CMPS. Sio Capital Management LLC lifted its holdings in shares of COMPASS Pathways by 211.7% in the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock valued at $5,762,000 after purchasing an additional 621,222 shares during the last quarter. Acuta Capital Partners LLC purchased a new stake in shares of COMPASS Pathways in the 3rd quarter valued at about $2,435,000. Walleye Capital LLC purchased a new stake in shares of COMPASS Pathways in the 3rd quarter valued at about $2,126,000. Polar Asset Management Partners Inc. lifted its holdings in shares of COMPASS Pathways by 83.3% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock valued at $3,576,000 after purchasing an additional 258,000 shares during the last quarter. Finally, Propel Bio Management LLC purchased a new stake in shares of COMPASS Pathways in the 3rd quarter valued at about $504,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Stock Performance

NASDAQ CMPS opened at $3.49 on Friday. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average is $4.02 and its two-hundred day moving average is $5.05. COMPASS Pathways plc has a 12-month low of $3.17 and a 12-month high of $10.64. The stock has a market capitalization of $323.43 million, a price-to-earnings ratio of -1.59 and a beta of 2.29.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Research analysts expect that COMPASS Pathways plc will post -2.33 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of COMPASS Pathways in a report on Tuesday, March 4th. Canaccord Genuity Group reduced their price objective on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, February 28th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Finally, Stifel Nicolaus began coverage on COMPASS Pathways in a research note on Thursday, February 27th. They set a “buy” rating and a $11.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $21.83.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.